期刊
EUROPEAN JOURNAL OF IMMUNOLOGY
卷 51, 期 2, 页码 331-341出版社
WILEY
DOI: 10.1002/eji.202048753
关键词
cancer immunotherapy; immune checkpoint inhibitors; LAG-3; pHLA-II; T cells
类别
资金
- Cancer Research UK (CRUK)
- Wales Cancer Research Centre
- Tenovus Cancer Care
- Life Sciences Research Network Wales studentship
- CRUK
- Cancer Research Wales
- Wellcome Trust
- Projekt DEAL
Immune checkpoint inhibitors have revolutionized the treatment of certain cancers, with combination approaches targeting multiple pathways showing increased efficacy. The newly identified immune checkpoint inhibitor LAG-3 interacts specifically with intact human leukocyte antigen class II heterodimers, providing insights into its function in initiating T cell inhibition.
Immune checkpoint inhibitors (antibodies that block the T cell co-inhibitory receptors PD-1/PD-L1 or CTLA-4) have revolutionized the treatment of some forms of cancer. Importantly, combination approaches using drugs that target both pathways have been shown to boost the efficacy of such treatments. Subsequently, several other T cell inhibitory receptors have been identified for the development of novel immune checkpoint inhibitors. Included in this list is the co-inhibitory receptor lymphocyte activation gene-3 (LAG-3), which is upregulated on T cells extracted from tumor sites that have suppressive or exhausted phenotypes. However, the molecular rules that govern the function of LAG-3 are still not understood. Using surface plasmon resonance combined with a novel bead-based assay (AlphaScreen(TM)), we demonstrate that LAG-3 can directly and specifically interact with intact human leukocyte antigen class II (HLA-II) heterodimers. Unlike the homologue CD4, which has an immeasurably weak affinity using these biophysical approaches, LAG-3 binds with low micromolar affinity. We further validated the interaction at the cell surface by staining LAG-3(+)cells with pHLA-II-multimers. These data provide new insights into the mechanism by which LAG-3 initiates T cell inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据